scholarly journals Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study

Cancer ◽  
2016 ◽  
Vol 123 (7) ◽  
pp. 1115-1123 ◽  
Author(s):  
Nour Sneige ◽  
Kenneth R. Hess ◽  
Asha S. Multani ◽  
Yun Gong ◽  
Nuhad K. Ibrahim
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Cohort Study ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Clinical Utility ◽  
Prognostic Significance ◽  
Growth Factor Receptor ◽  
Chromosome 17 ◽  
Epidermal Growth

Human Epidermal Growth Factor Receptor 2 Testing in Primary Breast Cancer in the Era of Standardized Testing: A Canadian Prospective Study

2014 ◽  
Vol 32 (35) ◽  
pp. 3967-3973 ◽  
Author(s):  
Wedad M. Hanna ◽  
Penny J. Barnes ◽  
Martin C. Chang ◽  
C. Blake Gilks ◽  
Anthony M. Magliocco ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Primary Breast Cancer ◽  
False Negative ◽  
Growth Factor Receptor ◽  
Chromosome 17 ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

Purpose Therapies that target overexpression of human epidermal growth factor receptor 2 (HER2) rely on accurate and timely assessment of all patients with new diagnoses. This study examines HER2 testing of primary breast cancer tissue when performed with immunohistochemistry (IHC) and additional in situ hybridization (ISH) for negative cases (IHC 0/1+). The analysis focuses on the rate of false-negative HER2 tests, defined as IHC 0/1+ with an ISH ratio ≥ 2.0, in eight pathology centers across Canada. Patients and Methods Whole sections of surgical resections or tissue microarrays (TMAs) from invasive breast carcinoma tissue were tested by both IHC and ISH using standardized local methods. Samples were scored by the local breast pathologist, and consecutive HER2-negative IHC results (IHC 0/1+) were compared with the corresponding fluorescence or silver ISH result. Results Overall, 711 surgical excisions of primary breast cancer were analyzed by IHC and ISH; HER2 and chromosome 17 centromere (CEP17) counts were available in all cases. The overall rate of false-negative samples was 0.84% (six of 711 samples). Interpretable IHC and ISH scores were available in 1,212 cases from TMAs, and the overall rate of false-negative cases was 1.6% (16 of 978 cases). Conclusion Our observation confirms that IHC is an adequate test to predict negative HER2 status in primary breast cancer in surgical excision specimens, even when different antibodies and IHC platforms are used. The study supports the American Society of Clinical Oncology/College of American Pathologists and Canadian testing algorithms of using IHC followed by ISH for equivocal cases.

The prognostic significance of epidermal growth factor receptor expression in breast cancer

Surgery Today ◽  
1994 ◽  
Vol 24 (10) ◽  
pp. 889-894 ◽  
Author(s):  
Masakuni Noguchi ◽  
Yuji Mizukami ◽  
Kazuo Kinoshita ◽  
Mitsuharu Earashi ◽  
Michael Thomas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Prognostic Significance ◽  
Growth Factor Receptor ◽  
Receptor Expression ◽  
Epidermal Growth
Sign in / Sign up

Export Citation Format

Share Document